Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B4: Autoimmune CAR-T Frontier (Design Logic, Disease Buckets, and Company Landscape) [Expert]

Prefer the overview first?
→ A4: Why CAR-T expands beyond cancer (autoimmunity as “reset”)

“Autoimmune CAR: Reset Toolkit (Target × Durability × Safety)”

Executive summary

Autoimmune CAR-T is shifting the goal from “killing tumor cells” to resetting immune circuitry and enabling durable remission. That changes both design priorities and operational constraints.

• The center of gravity is CD19 (B-cell targeting), reinforced by high-impact refractory SLE CD19 CAR-T reports and the subsequent wave of industry development.
• A practical industry frame includes Kyverna (KYV-101) and Cabaletta (CABA-201), both emphasizing fully human CD19 CAR-T concepts and severe autoimmune positioning.
• A distinct design path is BCMA-directed mRNA CAR-T (Cartesian’s Descartes-08), highlighting outpatient delivery, no preconditioning, and repeat dosing as a safety/operations strategy.
• Long-term follow-up (LTFU) is not optional; FDA’s LTFU guidance frames how sponsors plan for delayed risks in gene-modified therapies.

1) The coordinate system: Target × Durability × Safety/Operations

Target

• CD19: broad B-cell depletion logic (upstream driver in many autoantibody patterns)
• BCMA: plasma-cell/antibody-production axis (notably discussed in neurologic autoimmunity contexts)

Durability

• Integrating CAR-T: deep depletion → immune reconstitution/reset concept
• Transient mRNA CAR-T: controllability + outpatient repeat dosing (Descartes-08 narrative)

Safety/Operations

• conditioning intensity, monitoring pathway, and LTFU design are core value drivers

2) Disease buckets: where programs look most “real”

2.1 Autoantibody/B-cell–driven disease (SLE / lupus nephritis)

Refractory SLE CD19 CAR-T reports catalyzed the “immune reset” thesis and industry investment.
Kyverna positions KYV-101 (fully human anti-CD19 CAR-T) for B-cell–driven autoimmune disease including lupus nephritis, with trial information publicly documented.

2.2 Systemic/organ-damage disease (myositis / systemic sclerosis)

Cabaletta’s CABA-201 framing explicitly references severe autoimmune arenas including SLE, myositis, and systemic sclerosis.

2.3 Neuro-immune (myasthenia gravis and beyond)

Descartes-08 (BCMA-directed mRNA CAR-T) is described in the context of generalized MG, with an outpatient, no-preconditioning, repeat-infusion model.

3) Design philosophies: how autoimmune CAR differs from oncology CAR

Fully human binders (immunogenicity/re-treatment logic)

Both Kyverna and Cabaletta emphasize fully human CD19 CAR constructs as part of an autoimmune-appropriate design narrative.

Conditioning as a competitive design choice

Autoimmunity often runs on a tighter safety margin; “how much conditioning is needed” becomes a defining question. Descartes-08 is explicitly discussed as being delivered without preconditioning in key reports.

Transient mRNA CAR as an alternative safety/ops solution

mRNA CAR strategies emphasize controllability and operational scalability through repeat outpatient dosing.

4) Regulation and long-term safety: LTFU is built-in

FDA’s LTFU guidance provides a formal framework for designing long-term follow-up in gene therapy products, which is highly relevant for gene-modified cell therapies as well.

Operational meaning:

• follow-up is part of the therapy package
• durability claims require time, not headlines
• scaling autoimmune cell therapy implies scaling LTFU and post-treatment operations

5) What to watch in 12–24 months

1. cross-disease reproducibility of CD19 CAR “reset” signals
2. durability of drug-free remission with longer follow-up windows
3. maturation of outpatient mRNA CAR delivery models
4. conditioning optimization trade-offs (safety vs depth of reset)

Primary sources

Kyverna KYV-101 (LN trial / Fast Track).
Cabaletta CABA-201 (pipeline / RESET).
Cartesian Descartes-08 (MG; mRNA CAR).
FDA LTFU guidance (2020).